600535 Tasly Pharmaceutical Group Co.,Ltd.
Closed 03-28 15:00:00
15.14
+0.17
+1.14%
High
15.27
Low
14.97
Vol
13.98M
Open
14.97
D1 Closing
14.97
Amplitude
2.00%
Mkt Cap
22.62B
Tradable Cap
22.62B
Total Shares
1.49B
T/O
212.00M
T/O Rate
0.94%
Tradable Shares
1.49B
P/B
1.9
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
暂无数据
News
New Post(s)
Profile
Tasly Gets China Clinical Trial Nod for Acute Ischemic Stroke Injection
MT Newswires Live · 03-14
Tasly Gets China Clinical Trial Nod for Acute Ischemic Stroke Injection
BRIEF-China Resources Sanjiu To Buy 28% Stake in Tasly
Reuters · 02-28
BRIEF-China Resources Sanjiu To Buy 28% Stake in Tasly
China Resources Sanjiu Medical & Pharmaceutical Says It Plans to Buy 28% Stake in Tasly
THOMSON REUTERS · 02-28
China Resources Sanjiu Medical & Pharmaceutical Says It Plans to Buy 28% Stake in Tasly
China Resources Sanjiu Gets SASAC Approval for Tasly Pharmaceutical Stake Acquisition
MT Newswires Live · 02-07
China Resources Sanjiu Gets SASAC Approval for Tasly Pharmaceutical Stake Acquisition
Tasly Pharmaceutical Says China Resources Sanjiu Medical Gets State Asset Regulator's Approval for Buying Stake in Company
THOMSON REUTERS · 02-06
Tasly Pharmaceutical Says China Resources Sanjiu Medical Gets State Asset Regulator's Approval for Buying Stake in Company
BRIEF-China Resources Sanjiu Gets State Asset Regulator's Approval To Buy Stake In Tasly
Reuters · 02-06
BRIEF-China Resources Sanjiu Gets State Asset Regulator's Approval To Buy Stake In Tasly
Chinese Regulator Greenlights Tasly Pharmaceutical Stake Transfer
MT Newswires Live · 02-05
Chinese Regulator Greenlights Tasly Pharmaceutical Stake Transfer
BrainAurora Medical Technology Launches HK$583 Million Hong Kong IPO
MT Newswires Live · 2024-12-30
BrainAurora Medical Technology Launches HK$583 Million Hong Kong IPO
Tasly Pharmaceutical Subsidiary Gets Drug Registration for Muscle Spasms Drug
MT Newswires Live · 2024-12-05
Tasly Pharmaceutical Subsidiary Gets Drug Registration for Muscle Spasms Drug
Load more
Introduction
Company Name.
天士力医药集团股份有限公司
Industry:
医药制造业
Listing Date:
2002-08-23
Main Business:
天士力医药集团股份有限公司主营业务为药品的研发、生产和销售。公司产品主要有复方丹参滴丸、养血清脑颗粒、养血清脑丸、芪参益气滴丸、注射用益气复脉、水林佳等药品。公司荣获国家卫健委百姓健康频道“2024中医药品牌影响力奖”Top20榜第7名,“新医视”私域生态获评“年度数字营销之星”。报告期内,公司荣获“2024医药工业综合竞争力百强”、“2024中成药工业综合竞争力50强”、“2023年度中国医药工业百强”、“2023年度中国中药企业TOP100”、“2024中国药品研发综合实力50强”、“2024中国中药研发实力10强”、“2024中国化药研发实力100强”、“2024中国生物药研发实力50强”、“2023-2024年度医药行业自主创新前五十家企业”、“2023-2024年度制药工业企业营业收入前百家”等荣誉奖项;“中医药国际(一带一路)注册路径与关键技术”荣获中国科学技术协会2023年“科创中国”先导技术(生物医药领域)榜单;在可持续发展方面,公司入选中国上市公司协会“2024上市公司可持续发展最佳实践案例”,并荣获“ESG金牛奖百强”,公司“心动力量——重走长征路基层赋能系列公益活动”评选为2024“CSR竞争力”责任典型案例精选、年度社会责任贡献企业奖、2024年度最佳公益项目奖、2024人民企业社会责任奖。
Issue price:
14.70
Invest in Global Markets with Tiger Brokers!
Open App
{"stockData":{"symbol":"600535","market":"SH","secType":"STK","nameCN":"Tasly Pharmaceutical Group Co.,Ltd.","latestPrice":15.14,"timestamp":1743145200000,"preClose":14.97,"halted":0,"volume":13976054,"delay":0,"changeRate":0.0114,"floatShares":1494000000,"shares":1494000000,"eps":0.5624,"marketStatus":"Closed","change":0.17,"latestTime":"03-28 15:00:00","open":14.97,"high":15.27,"low":14.97,"amount":212000000,"amplitude":0.02,"askPrice":15.15,"askSize":639,"bidPrice":15.14,"bidSize":163,"shortable":0,"etf":0,"ttmEps":0.5624,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743384600000},"marketStatusCode":5,"adr":0,"adjPreClose":14.97,"symbolType":"stock","openAndCloseTimeList":[[1743125400000,1743132600000],[1743138000000,1743145200000]],"highLimit":16.47,"lowLimit":13.47,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1493950005,"isCdr":false,"pbRate":1.9,"roa":"--","peRate":26.920341,"roe":"7.68%","epsLYR":0.64,"committee":-0.3703,"marketValue":22618000000,"turnoverRate":0.0094,"status":0,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2025-03-31.","floatMarketCap":22618000000},"requestUrl":"/m/hq/s/600535","defaultTab":"news","newsList":[{"id":"2519811686","title":"Tasly Gets China Clinical Trial Nod for Acute Ischemic Stroke Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2519811686","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519811686?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 11:20","pubTimestamp":1741922414,"startTime":"0","endTime":"0","summary":"China has granted Tasly Pharmaceutical clinical trial approval for its allogeneic adipose-derived mesenchymal stromal cell injection for acute ischemic stroke, according to a Friday filing with the Shanghai Stock Exchange.The drug activates vascular regeneration and functional repair of damaged brain tissue in stroke patients, the filing said.Tasly's injection has also been approved for clinical trial in the US in October 2024, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0012","BK0196","600535","BK0188","BK0239","BK0028","BK0183"],"gpt_icon":0},{"id":"2514192322","title":"BRIEF-China Resources Sanjiu To Buy 28% Stake in Tasly","url":"https://stock-news.laohu8.com/highlight/detail?id=2514192322","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514192322?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 21:46","pubTimestamp":1740750384,"startTime":"0","endTime":"0","summary":"BRIEF-China Resources Sanjiu To Buy 28% Stake in TaslyFeb 28 - China Resources Sanjiu Medical & Pharmaceutical Co Ltd 000999.SZ:SAYS IT PLANS TO BUY 28% STAKE IN TASLY PHARMACEUTICAL GROUP CO LTDCHINA RESOURCES SANJIU SAYS IT IS SET TO BECOME TASLY'S CONTROLLING SHAREHOLDER AFTER THE TRANSACTION, CHINA RESOURCES TO BECOME TASLY'S ACTUAL CONTROLLERSource textFurther company coverage: 000999.SZ ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL3N3PJ15H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0185","BK0060","BK0012","000999","BK0010","BK0196","600535","BK0188","BK0239","BK0028","BK0183","BK0175"],"gpt_icon":0},{"id":"2514996324","title":"China Resources Sanjiu Medical & Pharmaceutical Says It Plans to Buy 28% Stake in Tasly","url":"https://stock-news.laohu8.com/highlight/detail?id=2514996324","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514996324?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 21:44","pubTimestamp":1740750249,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL3N3PJ15H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK0188","000999","BK0010","600535","BK0012","BK0183","BK0175","BK0060","BK0185","BK0028","BK0196"],"gpt_icon":0},{"id":"2509765996","title":"China Resources Sanjiu Gets SASAC Approval for Tasly Pharmaceutical Stake Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2509765996","media":"MT Newswires Live","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509765996?lang=en_us&edition=full_marsco","pubTime":"2025-02-07 13:47","pubTimestamp":1738907237,"startTime":"0","endTime":"0","summary":"China Resources Sanjiu received approval from China's State-owned Assets Supervision and Administration Commission for its acquisition of shares in Tasly Pharmaceutical Group , according to filings with the Shanghai and Shenzhen bourses.The deal involves purchasing shares from seven entities.The transaction is subject to board and shareholder approvals.Shares of China Resources Sanjiu rose 2% in recent trade on the Shenzhen bourse, while those of Tasly Pharmaceutical climbed 1% on the Shanghai bourse.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0010","000999","BK0188","BK0175","BK0196","BK0239","BK0185","BK0028","BK0012","600535","BK0060","BK0183"],"gpt_icon":0},{"id":"2509244909","title":"Tasly Pharmaceutical Says China Resources Sanjiu Medical Gets State Asset Regulator's Approval for Buying Stake in Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2509244909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509244909?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 17:10","pubTimestamp":1738833012,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nL4N3OX0U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0188","BK0028","600535","BK0185","BK0175","BK0060","BK0012","BK0196","BK0183","BK0239","BK0010","000999"],"gpt_icon":0},{"id":"2509244486","title":"BRIEF-China Resources Sanjiu Gets State Asset Regulator's Approval To Buy Stake In Tasly","url":"https://stock-news.laohu8.com/highlight/detail?id=2509244486","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509244486?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 17:10","pubTimestamp":1738833012,"startTime":"0","endTime":"0","summary":"BRIEF-China Resources Sanjiu Gets State Asset Regulator's Approval To Buy Stake In TaslyFeb 6 - Tasly Pharmaceutical Group Co Ltd 600535.SS:SAYS CHINA RESOURCES SANJIU MEDICAL & PHARMACEUTICAL CO LTD 000999.SZ GETS STATE ASSET REGULATOR'S APPROVAL FOR BUYING STAKE IN COMPANYSource textFurther company coverage: 600535.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nL4N3OX0U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","600535","000999","BK0028","BK0196","BK0060","BK0188","BK0010","BK0185","BK0239","BK0175","BK0012"],"gpt_icon":0},{"id":"2509442299","title":"Chinese Regulator Greenlights Tasly Pharmaceutical Stake Transfer","url":"https://stock-news.laohu8.com/highlight/detail?id=2509442299","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509442299?lang=en_us&edition=full_marsco","pubTime":"2025-02-05 11:52","pubTimestamp":1738727539,"startTime":"0","endTime":"0","summary":"Tasly Pharmaceutical Group said the acquisition of its 28% stake by China Resources Sanjiu was approved by China's State Administration for Market Regulation.China Resources Sanjiu recently received an official \"no prohibition\" decision from the regulator regarding its planned acquisition of a 28% stake in Tasly Pharma, according to a Wednesday filing with the Shanghai bourse.Following the transaction, the pharmaceutical company's controlling shareholder will change to China Resources Sanjiu from Tasly Group.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0183","BK0188","600535","BK0012","BK0239","BK0196"],"gpt_icon":0},{"id":"2495592779","title":"BrainAurora Medical Technology Launches HK$583 Million Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2495592779","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495592779?lang=en_us&edition=full_marsco","pubTime":"2024-12-30 16:14","pubTimestamp":1735546468,"startTime":"0","endTime":"0","summary":"BrainAurora Medical Technology launched its HK$583.2 million initial public offering in Hong Kong on Monday.The digital diagnostics and therapies provider is offering 181,112,000 shares at HK$3.22 apiece.BrainAurora secured four cornerstone investors, including Tasly Pharmaceuticals , which committed to subscribe to $48.5 million worth of IPO shares.The issuer expects to disclose the allocations on Jan. 7. It will start trading on the Hong Kong bourse on Jan. 8, according to a Monday filing.Deal proceeds will be used for research and development, clinical trials, technology upgrades, new cognitive centers, and working capital.CICC, SPDB International, CMBC International, Fosun International, GF Securities, and several others are the joint book-runners of the IPO.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0196","BK0239","BK0028","BK0012","06681","BK0183","600535"],"gpt_icon":0},{"id":"2489310685","title":"Tasly Pharmaceutical Subsidiary Gets Drug Registration for Muscle Spasms Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2489310685","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489310685?lang=en_us&edition=full_marsco","pubTime":"2024-12-05 12:04","pubTimestamp":1733371492,"startTime":"0","endTime":"0","summary":"Tasly Pharmaceutical Group (SHA:600535) subsidiary Jiangsu Diyi obtained drug registration for baclofen oral solution from China's drug administrator.Baclofen is indicated for severe but reversible muscle spasms caused by multiple sclerosis, according to a Thursday filing with the Shanghai bourse.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0183","BK0196","BK0012","BK0028","600535","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2002-08-23","address":"天津市北辰区普济河东道2号(天士力现代中药城)","stockEarnings":[{"period":"1week","weight":0.0156},{"period":"1month","weight":0.039},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0454},{"period":"1year","weight":0.011},{"period":"ytd","weight":0.0613}],"companyName":"天士力医药集团股份有限公司","boardCode":"AI0027","perCapita":"22599股","boardName":"医药制造业","registeredCapital":"149395万元","compareEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":-0.0086},{"period":"3month","weight":-0.0144},{"period":"6month","weight":0.0854},{"period":"1year","weight":0.1131},{"period":"ytd","weight":-0.0001}],"survey":" 天士力医药集团股份有限公司主营业务为药品的研发、生产和销售。公司产品主要有复方丹参滴丸、养血清脑颗粒、养血清脑丸、芪参益气滴丸、注射用益气复脉、水林佳等药品。公司荣获国家卫健委百姓健康频道“2024中医药品牌影响力奖”Top20榜第7名,“新医视”私域生态获评“年度数字营销之星”。报告期内,公司荣获“2024医药工业综合竞争力百强”、“2024中成药工业综合竞争力50强”、“2023年度中国医药工业百强”、“2023年度中国中药企业TOP100”、“2024中国药品研发综合实力50强”、“2024中国中药研发实力10强”、“2024中国化药研发实力100强”、“2024中国生物药研发实力50强”、“2023-2024年度医药行业自主创新前五十家企业”、“2023-2024年度制药工业企业营业收入前百家”等荣誉奖项;“中医药国际(一带一路)注册路径与关键技术”荣获中国科学技术协会2023年“科创中国”先导技术(生物医药领域)榜单;在可持续发展方面,公司入选中国上市公司协会“2024上市公司可持续发展最佳实践案例”,并荣获“ESG金牛奖百强”,公司“心动力量——重走长征路基层赋能系列公益活动”评选为2024“CSR竞争力”责任典型案例精选、年度社会责任贡献企业奖、2024年度最佳公益项目奖、2024人民企业社会责任奖。","serverTime":1743181112532,"listedPrice":14.7,"stockholders":"66106人(较上一季度减少3.43%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tasly Pharmaceutical Group Co.,Ltd.(600535),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tasly Pharmaceutical Group Co.,Ltd.(600535) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tasly Pharmaceutical Group Co.,Ltd.,600535,Tasly Pharmaceutical Group Co.,Ltd.股票,Tasly Pharmaceutical Group Co.,Ltd.股票老虎,Tasly Pharmaceutical Group Co.,Ltd.股票老虎国际,Tasly Pharmaceutical Group Co.,Ltd.行情,Tasly Pharmaceutical Group Co.,Ltd.股票行情,Tasly Pharmaceutical Group Co.,Ltd.股价,Tasly Pharmaceutical Group Co.,Ltd.股市,Tasly Pharmaceutical Group Co.,Ltd.股票价格,Tasly Pharmaceutical Group Co.,Ltd.股票交易,Tasly Pharmaceutical Group Co.,Ltd.股票购买,Tasly Pharmaceutical Group Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tasly Pharmaceutical Group Co.,Ltd.(600535),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tasly Pharmaceutical Group Co.,Ltd.(600535) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}